Sign up for our daily Newsletter and stay up to date with all the latest news!

Subscribe I am already a subscriber

You are using software which is blocking our advertisements (adblocker).

As we provide the news for free, we are relying on revenues from our banners. So please disable your adblocker and reload the page to continue using this site.
Thanks!

Click here for a guide on disabling your adblocker.

Sign up for our daily Newsletter and stay up to date with all the latest news!

Subscribe I am already a subscriber

CAN: MariMed closes $35M credit facility

MariMed closed a $35 million secured credit facility with Chicago Atlantic Advisors as the lead lender.

“I am delighted to announce the closing of this transformative credit facility,” said Jon Levine, MariMed President, and Interim Chief Executive Officer. “MariMed is known for its operational and financial discipline, resulting in one of the strongest balance sheets in the cannabis industry, enabling us to secure this funding. While we are capable of funding our current growth plans with cash flow from operations, the time is right to raise capital and accelerate these plans, which we believe will result in meaningful returns to our shareholders.”

  • MariMed closed a $35 million credit facility with a three-year maturity and the ability to extend to a five-year maturity under certain conditions.
  • MariMed borrowed $30 million at close and can draw down up to an additional $5 million over the next six months.
  • Funds will be used for completing the build-out of a new cultivation and processing facility in Illinois and a new processing kitchen in Missouri, expanding existing cultivation and processing facilities in Massachusetts and Maryland, funding other capital expenditures, and repaying in full the Kind Therapeutics seller notes from the Maryland acquisition in April 2022, with the remaining balance to be used for acquisitions.
  • Facility bears interest at a floating rate based on the bank prime rate plus 5.75% and includes 30% warrant coverage priced at a 20% premium.
  • The Company’s Debt/EBITDA ratio based on the midpoint of the Company’s 2022 annual EBITDA guidance is now 1.5X.
  • MariMed can repay the principal loan balance without penalty after the first 20 months.

“This credit facility allows us to significantly accelerate the completion of our expansion projects, which we believe will drive meaningful Revenue and EBITDA growth in 2023 and beyond,” said Susan Villare, MariMed’s Chief Financial Officer. “Including this facility, our blended interest rate1 of 10.5% and Debt/EBITDA ratio of 1.5X remain among the lowest in the cannabis industry and speak to the strength of our balance sheet and our ability to generate significant positive cash flow from operations.”

John Mazarakis, Partner of Chicago Atlantic, added, “We are excited to support the growth of MariMed. The team has consistently demonstrated its ability to profitably expand across an attractive six-state footprint for the benefit of its patients and adult-use customers. We look forward to significantly growing our investment with them in the future.” 

Chicago Atlantic acted as Lead Arranger with Silver Spike Investment Corp. for the senior secured credit facility. Chicago Atlantic is also the Administrative Agent for the credit facility.

Echelon Capital Markets acted as the financial advisor to MariMed in the arrangement of the senior secured credit facility.

The blended interest rate is calculated as the weighted average rate of all interest-bearing loans, mortgages, and the first draw of the $35 million credit facility and excludes the Kind Therapeutics seller notes, which will be settled with funds from the initial $30 million draw of the $35 million credit facility.

For more information:
MariMed
www.marimedinc.com    

Publication date: